Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel drug discovery leverages SIMDAT Grid technology

18.09.2008
Step change in life sciences. Within the European SIMDAT project, at GlaxoSmithKline (GSK) a substantial progress in pharmaceutical analysis has been achieved.

It enables pharmaceutical companies to Virtualise and Globalise their Research and Development (R&D) chain, lowering costs as well as considerably improving knowledge exchange between industrial and academic partners.

“One of the most important R&D strategies to achieve a significant gain of efficiency is to tap into external knowledge and expertise through a network of external alliances, sharing the risk, reward and control. Given the large investments in drug research, Virtualisation provides a great savings potential,” summarizes Professor Ulrich Trottenberg, director of Fraunhofer Institute for Algorithms and Scientific Computing SCAI, the SIMDAT project co-ordinator, the current challenges in pharmaceutical drug discovery.

“With the distributed nature and diverse location of biological data for disease and medical treatment, it is becoming vital to be able to fast and flexible connect to these resources. Grid as a key part of Information Technology supports the organisations’ rapid movement into the virtualised and now more globalised information market,” says Rob Gill, Head of Biology Domain Architecture at GSK. “The SIMDAT Grid technologies developed by GlaxoSmithKline (GSK), NEC, Inpharmatica (Galapagos), InforSense and Fraunhofer Institute for Algorithms and Scientific Computing SCAI provide a new business model in the life science sector, which can be considered as a success of the project as a whole.”

Usually, establishing new relationships by creating a new virtual organisation (VO) may take up to several months. But the “Data Grid” paradigm can reduce this to weeks or even days. The VO in this case demonstrates how a pharmaceutical company could partner with an academic group and a vendor company to look at a specific disease and drug target. The duration of this relationship depends on the questions asked and the costs incurred by the interaction. Biotech, on the other hand, has the opportunity to get access to new markets and, hence, is in the position to increase its commercial offer by implementing a finer grained product portfolio.

Knowledge exchange within SIMDAT is not bound to local infrastructure but is tending away from organisational, process and technology limitations. Thus, pharmaceutical companies like GSK have now the possibility to scale their business relationship with both biotech companies like Inpharmatica (Galapagos) and academic partners. That is, they can restrict themselves to exactly those resources they are interested in and are not forced to subscribe to a complete and costly product. This can be realised by new, grid-based middleware components, used to securely and transparently integrate distributed data repositories, in combination with distributed execution of process chains.

Through Virtualisation pharmaceutical companies like GSK are now capable of scaling their business relationship with both industrial and academic partners and take advantage of its great savings potential. In addition Globalisation is getting more and more crucial to keep up in an international context, especially considering the rate of growth of scientific and technical graduates in Asia is already outpacing the United States and Europe. Virtualisation has also the means to benefit from this wealth of knowledge along with developments in the global market.

Current industry applications can already take advantage of SIMDAT technologies. This was successfully demonstrated by a workflow-based test system implemented at GSK by InforSense, consisting of five different remote sites and including data services of two external companies. The development of this workflow is driven by the need to get high quality, state of the art analysis for pharmaceutical companies from wherever it is best sourced. Thus was shown that pharmaceutical R&D processes can be outsourced across multiple organizations, even if they are using different specifications. Thereby the central industrial requirement for a controlled and secure interaction has been fully addressed through internet security models provided by NEC.

As a powerful tool for knowledge exchange, SIMDAT technology broadens the scope of the drug discovery chain and is able to import the best of bread analysis from both academia and vendors at appropriate costs. It is an ideal showcase for potential providers who are interested in working with pharmaceutical partners in a more collaborative and beneficial manner rather than purely in a simple vendor consumer relationship.

SIMDAT has received research funding by the European Commission under the Information Society Technologies Programme (IST), contract number IST-2004-511438. Maximum Community contribution to project: 11 Mio Euro, Project start: 1 September 2004, Duration: 48 months, Partners involved: 27. The project is coordinated by the Fraunhofer Institute SCAI in Sankt Augustin, Germany.

Michael Krapp | Fraunhofer-Gesellschaft
Further information:
http://www.scai.fraunhofer.de
http://www.simdat.eu

Further reports about: Algorithms Computing GSK GlaxoSmithKline Grid Inpharmatica SCAI SIMDAT drug discovery

More articles from Information Technology:

nachricht Metamolds: Molding a mold
20.08.2018 | Institute of Science and Technology Austria

nachricht Robots as Tools and Partners in Rehabilitation
17.08.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Information Technology >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: It’s All in the Mix: Jülich Researchers are Developing Fast-Charging Solid-State Batteries

There are currently great hopes for solid-state batteries. They contain no liquid parts that could leak or catch fire. For this reason, they do not require cooling and are considered to be much safer, more reliable, and longer lasting than traditional lithium-ion batteries. Jülich scientists have now introduced a new concept that allows currents up to ten times greater during charging and discharging than previously described in the literature. The improvement was achieved by a “clever” choice of materials with a focus on consistently good compatibility. All components were made from phosphate compounds, which are well matched both chemically and mechanically.

The low current is considered one of the biggest hurdles in the development of solid-state batteries. It is the reason why the batteries take a relatively long...

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

A novel synthetic antibody enables conditional “protein knockdown” in vertebrates

20.08.2018 | Life Sciences

Metamolds: Molding a mold

20.08.2018 | Information Technology

It’s All in the Mix: Jülich Researchers are Developing Fast-Charging Solid-State Batteries

20.08.2018 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>